LPCN news

Lipocine reported a third quarter net loss of $0.7 million and announced successful FDA feedback for its BRLIZIO NDA, while Health Canada approved TLANDO for Canada.

Lipocine began its BLOOM Phase 3 trial for LPCN 1154 to support a potential 505(b)(2) NDA, utilizing existing resources despite past data anomalies.

Lipocine management will present at the H.C. Wainwright conference in September 2026. This event highlights the company's pipeline and upcoming clinical progress, potentially offering investors insights into future developments.

Lipocine reported that its oral brexanolone candidate for postpartum depression failed to meet its primary endpoint in a recent Phase 3 study. However, management suggested excluding an anomaly at one site would validate the drug's efficacy and plans new clinical studies and regulatory meetings.

Lipocine Inc. announced the appointment of former Johnson & Johnson executive and biotech director Michael J. Grissinger, effective August 3, 2026. This strategic addition strengthens the company’s corporate development and dealmaking capabilities to advance its pipeline.

Lipocine will host a virtual event on June 12, 2026 featuring key opinion leaders discussing unmet needs in postpartum depression and the clinical profile of its investigational oral brexanolone LPCN 1154. The company will present Phase 3 topline results and discuss potential market positioning of t…

Lipocine Inc. submitted exhibit 99.1 as part of an 8-K filing with the Securities and Exchange Commission. The filing indicates a corporate disclosure or announcement requiring investor notification.

Lipocine announced that Phase 3 clinical data for LPCN 1154, an oral brexanolone candidate for postpartum depression, was accepted for oral and poster presentations at the American Society of Clinical Psychopharmacology Annual Meeting in May 2026. The presentation will showcase results from the comp…